Mitoquinone mesylate 米托蒽醌甲磺酸盐; MitoQ mesylate; MitoQ10 mesylate|cas:845959-50-4|西域试剂

Mitoquinone mesylate 米托蒽醌甲磺酸盐; MitoQ mesylate; MitoQ10 mesylate,98.45%

产品编号：Bellancom-100116A| CAS NO：845959-50-4| 分子式：C₃₈H₄₇O₇PS| 分子量：678.81

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100116A	￥1100.00	杭州北京（现货）
Bellancom-100116A	￥1850.00	杭州北京（现货）
Bellancom-100116A	￥3900.00	杭州北京（现货）
Bellancom-100116A	￥6900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mitoquinone mesylate 米托蒽醌甲磺酸盐; MitoQ mesylate; MitoQ10 mesylate

产品介绍

Mitoquinone mesylate是一种基于TPP的线粒体靶向抗氧化剂，可防止氧化损伤。

生物活性

Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage.

体外研究

Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant.The optimal doses for Mitoquinone (MitoQ) and DecylTPP treatment are selected from dose-response experiments during 4-h cold storage (CS). The potential protective benefits of Mitoquinone treatment against CS injury are tested initially using MitoSOX Red, a mitochondrial-targeted fluorescent dye that measures mitochondrial superoxide generation. Normal rat kidney (NRK) cells exposed to CS result in a ~2-fold increase in fluorescence due to mitochondrial superoxide compared with untreated cells. Mitoquinone offers significant protection against CS-induced mitochondrial superoxide generation; whereas the control compound DecylTPP does not offer any protection. Mitoquinone treatment markedly decreases mitochondrial superoxide generation, whereas kidneys treated with DecylTPP have comparable levels of mitochondrial superoxide to kidneys exposed to CS alone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Mitoquinone (MitoQ) treatment significantly reduces pancreatic oedema and neutrophil infiltration. MitoQ dose-dependently increases serum amylase with an approximate doubling at the higher dose. MitoQ treatment nearly doubles lung MPO activity induced by Caerulein with a significant increase of serum IL-6 levels also evident at 10 mg/kg (dose 1).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Oil

溶解性数据

In Vitro:

DMSO : 50 mg/mL (73.66 mM; Need ultrasonic)

H₂O : 8.33 mg/mL (12.27 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.4732 mL	7.3658 mL	14.7317 mL
5 mM	0.2946 mL	1.4732 mL	2.9463 mL
10 mM	0.1473 mL	0.7366 mL	1.4732 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 7.69 mg/mL (11.33 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.68 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (3.68 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (3.68 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明